Oxford vaccine: Phase-3 trial to begin in Pune next week, volunteers enrol

Under phase-II, trials were conducted at Bharti Vidyapeeth Medical College and also KEM Hospital in the city

oxford, vaccine trials, coronavirus, covid-19
Earlier this month, the SII had paused the clinical trials of the vaccine candidate in the country
Press Trust of India Pune
2 min read Last Updated : Sep 19 2020 | 7:45 PM IST

The phase-III human clinical trial of the Covid-19 vaccine developed by Oxford University and being manufactured by the Serum Institute of India (SII) will begin at the Sassoon General Hospital in Pune next week.

Dean of the state-run Sassoon General Hospital Dr Muralidhar Tambe told this to PTI on Saturday.

"The phase-III trial of 'Covishield' vaccine will begin at Sassoon hospital from next week. It is likely to start on Monday. Some volunteers have already come forward for the trial. Around 150 to 200 volunteers will be administered the vaccine candidate dose," he said.

"From Saturday, the hospital started enrolling volunteers for the trial. Those who are willing to volunteer for the vaccination should contact the hospital," he said.

Under phase-II, trials were conducted at Bharti Vidyapeeth Medical College and also KEM Hospital in the city.

The SII has partnered with British-Swedish pharma company AstraZeneca for manufacturing the Covid-19 vaccine candidate, developed by the University of Oxford.

Earlier this month, the SII had paused the clinical trials of the vaccine candidate in the country.

The Drugs Controller General of India (DCGI) had on September 11 directed the SII to suspend any new recruitment in the phase-II and III clinical trial of the vaccine till further orders after AstraZeneca paused the trials in other countries because of "an unexplained illness" in a participant in the study.

However, on September 15, the DCGI gave permission to the SII to resume clinical trial of the vaccine.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineSerum Institute of India

First Published: Sep 19 2020 | 7:45 PM IST

Next Story